START WITH THE ANSWER
Why can prescription EPA help when a fish-oil trial does not?
REDUCE-IT tested a specific prescription EPA product in statin-treated people with elevated triglycerides and high cardiovascular risk. Its benefit does not establish that an over-the-counter mixed fish oil is an interchangeable substitute.
What was added to what?
The trial was not comparing a supplement with doing nothing about cholesterol. Participants already received statin treatment and had a defined triglyceride range. The added intervention was icosapent ethyl, a purified EPA ethyl ester, rather than a generic mixture of EPA and DHA. This is a medication question within an existing prevention strategy. Removing the background treatment, changing the product or enrolling lower-risk people changes the question, even if the marketing category still says omega-3.
The size of the trial result
REDUCE-IT enrolled 8,179 participants and followed them for a median 4.9 years. Its primary composite outcome occurred in 17.2% of the EPA group and 22.0% of the placebo group, an absolute difference of 4.8 percentage points; the hazard ratio was 0.75. The absolute figures help show what the relative result means in this high-risk setting. They do not predict an identical absolute benefit in people whose starting risk is much lower or who take a different product.
Why more omega-3 is not a complete explanation
The NIH review places REDUCE-IT beside other cardiovascular trials. A separate high-dose EPA–DHA formulation in STRENGTH did not show the same benefit, despite a superficially similar omega-3 dose. Formulation, populations and comparison oils may contribute to differences; the reviewed evidence does not reduce the entire disagreement to one proven explanation. This is a useful case in which ingredient family and dose are insufficient descriptors. High-dose studies also reported more atrial fibrillation, so evaluating the intervention requires benefits and harms together.
A product comparison that stays clinically meaningful
For a short exercise, compare the wording prescription EPA with the label fish oil, then list what would need to match: active ingredient, formulation, trial population and background care. Do not use capsule count to simulate a prescription. A bottle’s nutritional composition cannot establish that it has the clinical evidence, manufacturing characteristics or use conditions of the tested medicine. The lesson is not that one category is universally good and another bad; it is that replacing a tested intervention with something that shares a keyword can erase the evidence supporting the decision.
What to take away
- REDUCE-IT tested a specific add-on medication in a high-risk population.
- Do not translate a prescription trial into a capsule-count substitution.
CHECK YOUR UNDERSTANDING
What is the absolute difference between 22.0% and 17.2%?
Think it through, then reveal the explanation
4.8 percentage points over the reported trial period, in the enrolled population. It is not 4.8% of every person’s individual risk.
A learning question, not a health assessment. No answers are collected or saved.
Original material & reading scope
Trial Bhatt et al. — Icosapent ethyl in REDUCE-IT
Original-paper abstract or result passages returned by web search. Direct open returned an empty page or access challenge; full text not reviewed.
Checked 2026-09-21 · 2019
Open original source Lessons using this sourceOfficial guidance NIH ODS — Omega-3 fatty acids: forms, trials and safety
Relevant sections of the official public reference page; not an independent clinical review.
Checked 2026-09-21 · Living source
Open original source Lessons using this source